IC
TVTX icon

Ikarian Capital’s Travere Therapeutics TVTX Stock Holding History

Ikarian Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-36,600
Closed -$1.4M – 210
2025
Q4 		$1.4M Sell
36,600
-177,900
-83% -$5.78M 0.11% 121
2025
Q3 		$5.13M Buy
+214,500
New +$4.03M 0.52% 46

Other funds holding TVTX

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $58.4B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Ikarian Capital's TVTX Position: Q4 2025 in Review

Ikarian Capital sold out of Travere Therapeutics (TVTX) in Q4 2025, closing a stake of 190,781 shares — an estimated $6.2M sold.

Ikarian Capital first reported a position in TVTX in Q4 2024 and held it in 2 quarters. The position peaked at $4.56M in Q3 2025. 278 funds tracked by Wall St. Rank hold TVTX as of Q4 2025.

  • Ikarian Capital reported no remaining Travere Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Ikarian Capital sold 190,781 Travere Therapeutics shares in Q4 2025, an estimated $6.2M.
  • Ikarian Capital first reported a position in Travere Therapeutics in Q4 2024 and held it in 2 quarters.
  • Ikarian Capital's Travere Therapeutics position peaked at $4.56M in Q3 2025.
  • 278 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2025.

Based on Ikarian Capital's 13F filing for Q4 2025, filed 18 Feb 2026.